Navigation Links
sanofi-aventis: Strong Performance of Growth Platforms in Q1 2011
Date:4/28/2011

he ratio of R&D expenses to net sales was 14.1%, down 0.4 percentage points versus the first quarter of 2010.

Selling and general expenses increased slightly by 1.7% at constant exchange rates (+5.1% on a reported basis) to euro 1,933 million. This evolution reflected on one hand decreased spend in Europe, a strong reduction in the U.S. which was partially compensated by investment in Allegra® OTC and increased promotional effort on Lantus® as well as excise fee in the U.S. and on the other hand continued investment in Emerging Markets The ratio of selling and general expenses to net sales was 24.8% compared to 23.3% in the first quarter of 2010, reflecting mainly the absence of A/H1N1 vaccines sales. General and Administrative expenses were flat during the period.

Other current operating income net of expenses was positive euro 16 million versus euro 75 million in the first quarter of 2010, which included a euro 87 million payment received from Teva on sales of Copaxone® in North America. These payments ceased at the end of the first quarter of 2010. In Q1 2011, this line included euro 42 million of advisory fees associated with the Genzyme acquisition.

The share of profits from associates reached euro 292 million, an increase of 20.2%. The share of after-tax profits from the territories managed by BMS under the Plavix® and Avapro® alliance was euro 274 million, up 19.6%, driven by the performance of Plavix® in the U.S. and a positive U.S. dollar impact.

Net income attributable to non-controlling interests was euro 78 million, stable versus Q1 2010. The pre-tax profits paid to BMS from territories managed by sanofi-aventis was euro 72 million versus euro 71 million in Q1 2010.

Business operating income was euro 3,027 million, down 10.2%, or 15.5% at constant exchange rates.

Net financial expenses were euro 78 mi
'/>"/>

SOURCE sanofi-aventis
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32

Related medicine technology :

1. Sanofi-aventis: Multaq(R) Approved in the European Union for Patients With Atrial Fibrillation
2. Reportlinker Adds Sanofi-Aventis: PharmaVitae Profile
3. Reportlinker Adds Sanofi-Aventis: PharmaVitae Profile
4. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
5. AspenBio Pharma Reports Strong Results with Appendicitis Triage Blood Test from Large Multiple Hospital Study
6. Boston Scientific PROMUS(TM) and TAXUS(R) Stents Continue Strong Performance in Safety and Efficacy Measures
7. HealthMedias Strongest Single Quarter Results: Growth Driven by Product Enhancements, New Partnerships
8. SPIRIT III Results Reaffirm Strong Performance of Boston Scientific PROMUS(TM) and TAXUS(R) Express(R) Stents
9. US Oncology Affiliated Physicians Make a Strong Showing in ASCO Proceedings
10. Groundbreaking American Journal of Play from Strong National Museum of Play(R) Premiers July 2008
11. Seventy Years Old and Going Strong With Down Syndrome and No Dementia: The Case of Mr. C Causes Major Interest in the Scientific Community
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... 2014  Low T Center endorses the recommendations ... Hyattsville, Maryland earlier this week. The ... patient population for testosterone therapy (TRT), as well ... TRT. Examining recent claims from studies that TRT affects ... studies do not provide convincing evidence that TRT ...
(Date:9/18/2014)... Ky. , Sept. 18, 2014 /PRNewswire/ ... innovative laboratory technologies and products to hospitals, ... announced today an amended distributorship agreement with ... reagents, controls and instruments, including the Sysmex ... Sysmex XP-300™, XT-Series and XN-Series Automated Hematology ...
(Date:9/18/2014)... Research and Markets  has announced the addition of ... Columns Market" report to their offering. ... enantiomers of the same compound with different affinities for ... possessing different elution times. Chiral stationary phases are generally ... chiral separation chromatography columns market is growing at a ...
Breaking Medicine Technology:Low T Center Endorses The Joint FDA Committee Meeting on Testosterone 2LABSCO Renews Sysmex Distributorship Agreement 2LABSCO Renews Sysmex Distributorship Agreement 3Micro Market Monitor: Global Chiral Separation Columns Market 2
... Feb. 7, 2011 Beckman Coulter, Inc. (NYSE: ... and marketer of products that simplify, automate and ... technology leader that designs, manufactures, and markets innovative ... commercial customers, announced today that they have entered ...
... (Nasdaq: GXDX ) announced today that the Federal ... under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ... Novartis to purchase all outstanding shares of common stock of ... the HSR Act waiting period satisfies one of the conditions ...
Cached Medicine Technology:Danaher to Acquire Beckman Coulter, Inc. 2Danaher to Acquire Beckman Coulter, Inc. 3Danaher to Acquire Beckman Coulter, Inc. 4Danaher to Acquire Beckman Coulter, Inc. 5FTC Grants Early Termination of Waiting Period Under Hart-Scott-Rodino Act 2
(Date:9/18/2014)... Mary Ann Thompson and Mathieu Nikel decided it was time to ... their son, Isaac, said there was only one choice for them ... 2001 when Thompson was an undergraduate student and needed a French ... time, was French and so she asked him. , ... when she was 7 years old. Nikel is originally from ...
(Date:9/18/2014)... Kent, WA Chiropractor Danene Saggau ... to announce that Dawn Kelly has agreed to become the ... looks forward to Ms. Kelly expanding her role within the ... her a key contributor. “ Dawn Kelly brings to ... personal experiences that will allow me to focus on ...
(Date:9/18/2014)... 2014 Memorial Cardiac and Vascular ... week by performing the first ever, adult heart transplant ... for Organ Sharing) approval to launch the adult heart ... two programs in South Florida. , The skilled ... Gongora, Medical Director of the Adult Heart Transplant ...
(Date:9/18/2014)... 18, 2014 (HealthDay News) -- Exposure to diverse communities ... study. Hearing different languages in the park ... to learn from people who are different from them, ... like adults, are often biased against interacting with and ... Amanda Woodward, a University of Chicago psychology professor, said ...
(Date:9/18/2014)... By Steven Reinberg HealthDay ... a sign that the Ebola outbreak in West Africa is starting ... that more than 700 new cases of the deadly viral infection ... number of cases to more than 5,300, with roughly half of ... reported. The number of deaths now tops 2,600. WHO ...
Breaking Medicine News(10 mins):Health News:For The First Time in Over a Decade Mercy College Alumni Marry at College 2Health News:Lake Meridian Chiropractic of Kent, WA Announces that Dawn Kelly Has Been Promoted to the Position of Office Manager 2Health News:Memorial Cardiac & Vascular Institute Performs First Adult Heart Transplant in Broward County 2Health News:Memorial Cardiac & Vascular Institute Performs First Adult Heart Transplant in Broward County 3Health News:Memorial Cardiac & Vascular Institute Performs First Adult Heart Transplant in Broward County 4Health News:Study: Exposure to Diversity Might Boost Baby's Social Skills 2Health News:New Ebola Cases Top 700 in Just One Week, Officials Report 2Health News:New Ebola Cases Top 700 in Just One Week, Officials Report 3
... of low health literacy the difference between patients, ... effectively communicate complex medical information is $106 billion ... biopharmaceutical company. To improve the health literacy of professionals ... health literacy study emphasis beginning this fall. The MU ...
... , ... Government Agencies to Increase ROI of IT Infrastructure , ... Reston, VA (PRWEB) February 18, 2010 -- Carahsoft ... Parabonâ Computation , a veteran provider of extreme-scale grid computing software and services. ...
... ... software standardization program at seven hospital laboratories of the Cleveland Clinic in Ohio. ... ... healthcare diagnostic information technology and outreach solutions, has successfully completed system-wide implementation of ...
... Rat studies suggest Victoza could spur rare thyroid tumor, ... THURSDAY, Feb. 18 (HealthDay News) -- The U.S. Food ... January to approve a new diabetes drug, Victoza (liraglutide), ... risk for a rare thyroid cancer. , Victoza, among ...
... (Feb. 17, 2010) Van Andel Research Institute ... sunitinib, a treatment that is currently the first line of ... form of kidney cancer. Most patients who show a ... after one year of treatment. Kidney cancer is among ...
... , ST. PETERS, Mo. , Feb. 18 ... Electronic Materials, Inc., has donated $25,000 to Meds & ... charity dedicated to saving the lives of Haiti ,s malnourished ... Kids produces peanut-based ready-to-use therapeutic food (RUTF) – known in ...
Cached Medicine News:Health News:MU offers training program to improve health literacy 2Health News:Parabon's Frontier Grid Platform Software Now Available on Carahsoft's GSA Schedule 2Health News:Parabon's Frontier Grid Platform Software Now Available on Carahsoft's GSA Schedule 3Health News:Sunquest Completes System-Wide Implementation at Cleveland Clinic Hospital Laboratories 2Health News:FDA Approved Diabetes Drug Despite Hints at Cancer Risk 2Health News:FDA Approved Diabetes Drug Despite Hints at Cancer Risk 3Health News:VARI findings may help patients with deadly kidney cancer 2Health News:MEMC Foundation Donates to Help Fight Malnourishment in Haiti 2Health News:MEMC Foundation Donates to Help Fight Malnourishment in Haiti 3
ELISA Test System for the detection of HBc...
Test for Anti-HBc for use on the Abbott Prism...
... flexible meter for Point of ... Accu-Chek Inform System offers user-friendly, ... the only Point of Care ... the entry and automatic transfer ...
... Introducing BenchMark XT® the only ... the flexibility you need to expand ... and improve your slide turnaround time. ... You choose how to use the ...
Medicine Products: